In vitro and in vivo effect of adriamycin therapy on monocyte activation by liposome-encapsulated immunomodulators.

No abstract is available for this paper.

• Publication year

  1988

• Venue

  Cancer Research

• Publication date

  1988-09-15

• Fields of study

  Medicine

• Identifiers
  PMID 3261632
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Adriamycin-induced activation of NK activity may initially involve LAF production

  2004cited by this paper
• Neoadjuvant chemotherapy of osteosarcoma: results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor response.

  1988cited by this paper
• Adjuvant chemotherapy for osteosarcoma: a randomized prospective trial.

  1987cited by this paper
• Augmentation of the generation of cell-mediated cytotoxicity after a single dose of adriamycin in cancer patients.

  1986cited by this paper
• Treatment of experimental lung metastasis with local thoracic irradiation followed by systemic macrophage activation with liposomes containing muramyl tripeptide.

  1986cited by this paper
• Macrophage cytotoxicity: interleukin 1 as a mediator of tumor cytostasis.

  1986cited by this paper
• Natural and recombinant human interleukin 1-beta is cytotoxic for human melanoma cells.

  1986cited by this paper
• Correlation between adriamycin-induced augmentation of interleukin 2 production and of cell-mediated cytotoxicity in mice.

  1986cited by this paper
• The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity.

  1986cited by this paper
• Interleukin 1 from human leukemic monocytes.

  1985cited by this paper
• Nile red: a selective fluorescent stain for intracellular lipid droplets

  1985cited by this paper
• Human interleukin 1 is a cytocidal factor for several tumor cell lines.

  1985cited by this paper
• Lysis of tumor cells by human blood monocytes by a mechanism independent of activation of the oxidative burst.

  1985cited by this paper
• Correlation of tumor growth inhibitory activity of macrophages exposed to adriamycin and adriamycin sensitivity of the target tumor cells.

  1984cited by this paper
• Lymphokine-activated human blood monocytes destroy tumor cells but not normal cells under cocultivation conditions.

  1984cited by this paper
• Cellular basis for adriamycin-induced augmentation of cell-mediated cytotoxicity in culture.

  1984cited by this paper
• Ultrastructural studies of the interaction between liposome-activated human blood monocytes and allogeneic tumor cells in vitro.

  1983cited by this paper
• Tumoricidal activity of human monocytes activated in vitro by free and liposome-encapsulated human lymphokines.

  1983cited by this paper
• Augmentation of the phagocytic activity of murine spleen cell populations induced by Adriamycin.

  1982cited by this paper
• Effect of L-phenylalanine mustard, adriamycin, actinomycin D, and 4'-(9-acridinylamino)methanesulfon-m-anisidide on naturally occurring human spontaneous monocyte-mediated cytotoxicity.

  1982cited by this paper
• Involvement of macrophages in the eradication of established metastases following intravenous injection of liposomes containing macrophage activators.

  1982cited by this paper
• Analysis of the fate of systemically administered liposomes and implications for their use in drug delivery.

  1982cited by this paper
• Monocyte cytotoxicity: evidence for multiple mechanisms of in vitro erythrocyte target killing. Trypan blue can both inhibit and enhance target lysis.

  1982cited by this paper
• Modulation of the cytotoxic response against allogeneic tumor cells in culture by adriamycin.

  1980cited by this paper
• Effects of adriamycin on the activity of mouse natural killer cells.

  1980cited by this paper
• Therapy of spontaneous metastases by intravenous injection of liposomes containing lymphokines.

  1980cited by this paper
• A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate.

  1979cited by this paper
• Adriamycin-induced antitumor response in lethally irradiated mice.

  1979cited by this paper
• Increased primary cell-mediated immunity in culture subsequent to adriamycin or daunorubicin treatment of spleen donor mice.

  1977cited by this paper
• Inhibition of pulmonary metastasis by intravenous injection of specifically activated macrophages.

  1974cited by this paper

• Translational history and hope of immunotherapy of canine tumors.

  2024cites this paper
• Correction to: Current Advances in Osteosarcoma.

  2020cites this paper
• Muramyl Tripeptide-Phosphatidyl Ethanolamine Encapsulated in Liposomes (L-MTP-PE) in the Treatment of Osteosarcoma.

  2020cites this paper
• Harnessing the untapped potential of nucleotide‐binding oligomerization domain ligands for cancer immunotherapy

  2018cites this paper
• Muramyl tripeptide-phosphatidyl ethanolamine encapsulated in liposomes (L-MTP-PE) in the treatment of osteosarcoma.

  2014cites this paper
• Mifamurtide for the treatment of nonmetastatic osteosarcoma

  2011cites this paper
• Mifamurtide

  2010cites this paper
• Mifamurtide in osteosarcoma--a practical review.

  2010cites this paper
• In Vitro and in Vivo Effect of Doxorubicin Combined with Liposome-encapsulated Muramyl Tripeptide on Canine Monocyte Activation 1

  2006cites this paper
• Impairment of lymphocyte locomotion in the tumor microenvironment and the effect of systemic immunotherapy with liposome-encapsulated myramyl-tripeptide-phosphatidylethanolamine

  2005cites this paper
• Effect of ibuprofen on monocyte activation by liposome-encapsulated muramyl tripeptide phosphatidylethanolamine (CGP 19835A): Can ibuprofen reduce fever and chills without compromising immune stimulation?

  2005cites this paper
• A nude mouse model of human osteosarcoma lung metastases for evaluating new therapeutic strategies

  2004cites this paper
• Update on the biology and management of canine osteosarcoma.

  2003cites this paper
• Long-term survival after intralesional resection and multi-modal therapy of thoracic spine osteosarcoma.

  2003cites this paper
• In Vitro and In Vivo Enhancement of Canine Pulmonary Alveolar Macrophage Cytotoxic Activity Against Canine Osteosarcoma Cells

  1999cites this paper
• Therapy of cancer metastasis by tumoricidal activation of tissue macrophages using liposome-encapsulated immunomodulators.

  1998cites this paper
• Establishment of an activated macrophage cell line, A-THP-1, and its properties.

  1998cites this paper
• Influence of liposomal muramyl tripeptide phosphatidylethanolamine on the changes of nucleic acids in the blood and hemopoietic tissues of irradiated mice.

  1995cites this paper
• Biologic therapy for osteosarcoma using liposome-encapsulated muramyl tripeptide.

  1995cites this paper
• Combination Therapy with Ifosfamide and Liposome‐Encapsulated Muramyl Tripeptide: Tolerability, Toxicity, and Immune Stimulation

  1995cites this paper
• Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine adjuvant immunotherapy for splenic hemangiosarcoma in the dog: a randomized multi-institutional clinical trial.

  1995cites this paper
• Current studies of liposome muramyl tripeptide (CGP 19835A lipid) therapy for metastasis in spontaneous tumors: a progress review.

  1994cites this paper
• Therapy of cancer metastasis by systemic activation of macrophages.

  1994cites this paper
• Clinical application of phospholipid liposomes containing macrophage activators for therapy of cancer metastasis

  1994cites this paper
• Effect of Adriamycin on liposomal muramyl tripeptide's ability to up-regulate monocyte cytokine expression

  1993cites this paper
• In vitro and in vivo effect of doxorubicin combined with liposome-encapsulated muramyl tripeptide on canine monocyte activation.

  1993cites this paper
• Liposome-encapsulated muramyl tripeptide: a new biologic response modifier for the treatment of osteosarcoma.

  1993cites this paper
• Pre- and postirradiation hemopoietic effects of liposomal muramyl tripeptide phosphatidylethanolamine (MTP-PE) administered to C57Bl/6 mice before irradiation.

  1993cites this paper
• The effect of liver macrophages on in vitro cytolytic activity of 5FU and FUdR on colon carcinoma cells: evidence of macrophage activation.

  1992cites this paper
• Modulation of tissue factor on human monocytes by cisplatin and adriamycin

  1992cites this paper
• In situ activation of mouse macrophages and therapy of spontaneous renal cell cancer metastasis by liposomes containing the lipopeptide CGP 31362

  1991cites this paper
• Comparative efficacy of liposomes containing synthetic bacterial cell wall analogues for tumoricidal activation of monocytes and macrophages

  1991cites this paper
• Influence of chemotherapy administration on monocyte activation by liposomal muramyl tripeptide phosphatidylethanolamine in children with osteosarcoma.

  1991cites this paper
• Optimization of the Liposomes Encapsulating a New Lipopeptide CGP 31362 for Efficient Activation of Tumoricidal Properties in Monocytes and Macrophages

  1991cites this paper
• Effect of recombinant human interleukin 4 on human monocyte activity.

  1990cites this paper
• Macrophages and cancer

  1990cites this paper
• Interaction of cancer chemotherapy agents with the mononuclear phagocyte system.

  1990cites this paper
• Induction of macrophage procoagulant expression by cisplatin, daunorubicin and doxorubicin

  1990cites this paper
• Activation of tumoricidal properties in monocytes from cancer patients following intravenous administration of liposomes containing muramyl tripeptide phosphatidylethanolamine.

  1989cites this paper